Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESPAC-6 adjuvant chemotherapy allocation trial in resected pancreatic cancer
2024-514682-19-00Phase 3Authorised
- Sponsor
- Heidelberg University Hospital
- Start
- Aug 2026
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of oxaliplatin and gemcitabine in pancreatic adenocarcinoma (PDAC) and pancreatic acinar cell carcinoma (PACC) (2 arms), sponsored by Heidelberg University Hospital. Primary endpoint: Disease-free survival. Planned start Aug 2026; status: authorised.
02
Drugs
oxaliplatingemcitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)pancreatic acinar cell carcinoma (PACC)
Beyond the preview
Go deeper on 2024-514682-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514682-19-00.